Stephen Dilly, M.D., Ph.D
CEO and President
Member, Board of Directors

Stephen Dilly joined APT as its CEO and president in April 2006. He has over 20 years of experience in the biotech space and is well-prepared to lead APT into its next stage of growth. Stephen previously served as the Senior Vice President of Development and Chief Medical Officer for Chiron BioPharma. He also held executive positions for Genentech and SmithKline Beecham. Throughout his career, Stephen has been closely associated with the successful development and launch of a wide array of important drugs, including: Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. He currently serves on the board of directors for Avigen, a biopharmaceutical company developing innovative therapies for neurological conditions. Stephen earned an M.D. from the University of London in 1982 and earned a Ph.D in cardiac physiology from the University of London in 1988.

Click below for information on
Teresa St. John
Executive Assistant/Office Manager

Howie Raff, Ph.D
COO

Howie Raff brings over 25 years of biotechnology research and development expertise to APT. Howie previously served as the Head of West Coast Operations for The Biologics Consulting Group and held executive positions for Chiron Corporation, including the role of Vice President, Development Management. He also spent 11 years in discovery research and development for Bristol-Myers Squibb. Howie has been involved with the development and approval of several drugs in the U.S. and Europe, including: CTLA4-lg, Proleukin, Menjugate vaccine and Cubicin. He earned a Ph.D in immunology from Washington State University and earned a fellowship from the Howard Hughes Medical Institute at the University of California – San Francisco . He currently serves on the board of LifeGen Technologies a Madison , WI based biotechnology company focused on discovering gene and biochemical changes that occur during aging and caloric restriction.

Charles Johnson, M.D.
Chief Medical Officer

Charles Johnson joined APT Pharmaceuticals after thirteen years of leading clinical development programs at Genentech. As Vice-President and head of the Immunology and Tissue Repair clinical group at Genentech from 2004-2007, Charlie was responsible for successful launches of Rituxan for RA and Lucentis for Age Related Macular Degeneration and for the continued development in multiple therapeutic areas for Pulmozyme, Growth Hormone, Activase/TNKase, Rituxan, Raptiva and Xolair. He lead the defense of the applications for approval of Xolair and Raptiva at the FDA. Before joining Genentech, Charlie was the director of the Cystic Fibrosis Center at Washington University in St. Louis. Charlie received his medical degree at the University of Cape Town in South Africa, gained Board certification in Pediatrics at the Red Cross War Memorial Children’s Hospital, and completed his Pediatric Pulmonology Fellowship at Washington University. He has testified before the Senate Subcommittee for Health on issues of patient protection in clinical research.

Ralph Niven, MBA, Ph.D.
Chief Technology Officer

Ralph Niven joins APT with almost two decades of experience, most recently consulting to biopharmaceutical companies on strategic, organizational and technical development initiatives. Prior to his consulting business he was Senior Vice President of Preclinical Development at Discovery Laboratories Inc. where he managed the West coast operations of the company. His team was responsible for several product candidates that reached clinical development. His career has also included roles of increasing responsibility at Amgen, Megabios and Advanced Inhalation Research (Alkermes). Ralph has authored approximately 50 peer-reviewed articles and holds over 10 patents. He earned a Ph.D in Pharmaceutical Sciences from the University of Kentucky and an MBA in healthcare from George Washington University.

Amy Burroughs Nader
Chief Commercial Officer
Head of Business Development

Amy Burroughs Nader joins APT with a wealth of health care business experience and knowledge in product commercialization. Prior to APT, Amy spent six years at Genentech in roles of increasing responsibility. She was most recently the Commercial Team Leader for the Genentech/Biogen Idec collaboration in multiple sclerosis which included preparing for a launch in PPMS and developing a phase III program in RRMS. Before joining Genentech, Amy was in marketing leadership roles at ePhysician, American WholeHealth, Athena Healthcare and Procter & Gamble. Amy earned her Bachelor’s degree, cum laude, in Computer Science from Dartmouth College and an MBA from Harvard Business School where she graduated as a Baker Scholar. She served as a fellow at HBS in health care and entrepreneurial finance under the direction of Regina Herzlinger.

Sue Barrowcliffe
Executive Vice President of Development, Europe
and Global Head of Regulatory Affairs

Sue brings to APT over 20 years experience in global regulatory affairs and drug development gained in both large pharma and small biotech companies. Sue’s previous roles have included Vice President of Global Product Registration for SmithKline Beecham, VP European Regulatory Affairs for Chiron, Director of Drug Development for British Biotech and CEO pf Pharminox a small start up oncology company based in the UK. Sue’s experience covers a wide range of drug development activities from the start up of clinical trials to global marketing approval. She has led the registration of a large number new products across a variety of therapy areas including anti-infectives, oncology, diabetes , CNS and cardiovascular. Sue currently also runs her own regulatory consultancy business as well as remaining as non-executive director of Pharminox. Sue has a bachelor’s degree (with honours) in biochemistry from the University of Sheffield, UK.

Joe Melvin
Head of Finance, Planning & Analysis

Joe Melvin joined APT Pharmaceuticals in February 2008 as Head of Finance, Planning & Analysis. He brings to this position more than 10 years of experience in drug development strategy, market assessment and finance. Prior to joining APT, Joe was a management consultant with SDG (now part of IMS Health) for 6 years, during which time he participated in or led some twenty consulting engagements at more than a dozen pharmaceutical and biotech clients in the US, Europe and Japan. The decisions taken by executives at these companies on Joe’s advice have directly impacted the treatment options available to tens of millions of people worldwide. He later joined Chiron Corporation and was promoted to lead the strategy & planning function of the company’s $600 million therapeutics business. Shortly after Chiron’s acquisition by Novartis, Joe was recruited by Becton, Dickenson & Co. to spearhead the global diagnostic maker’s expansion into clinical trials support and “companion diagnostics.” Joe holds a bachelor’s degree in engineering from MIT and a MBA from Stanford’s Graduate School of Business.

Teresa St. John
Executive Assistant/Office Manager

Teresa has many years of administrative experience in various size companies, from start-ups to large corporations, chiefly in the pharmaceutical and computer industries. In addition to Executive Administrative positions, other titles she has held include Document Control Specialist for Questcor Pharmaceuticals, Telecommunications Administrator/Remote Access for Openwave Systems, Manager of Professional Services Administration for USoft, and Professional Services, Manager, Training & Consulting Programs and Business Manager – Professional Services for Uniface Corporation.